Hepatoma (Hepatocellular Carcinoma): Causes, Symptoms and Treatments

Hepatoma, also known as hepatocellular (liver) carcinoma (HCC), is one of the most common and deadliest liver cancers, accounting for more than 80% of primary liver cancer cases worldwide. Every year, it affects over 900,000 people, with a high mortality rate due to late-stage diagnosis. 

This article explores hepatoma in detail, covering its causes, symptoms, diagnosis, and available treatments to help patients, caregivers, and healthcare providers better understand this condition.

[signup]

What is Hepatoma?

Hepatoma, or hepatocellular carcinoma (HCC), is a cancer that starts in the liver cells (hepatocytes). It is a primary liver cancer, meaning it originates in the liver rather than spreading from another part of the body.

Types of Hepatoma

Hepatoma can be classified into different types based on its growth pattern and spread. Understanding these distinctions helps in choosing the most effective treatment approach. Types of HCC include:

• Unifocal HCC: A single tumor confined to the liver.
• Multifocal HCC: Multiple tumors spread throughout the liver.
• Diffuse HCC: Cancer that is widespread, making treatment more difficult.
• Fibrolamellar HCC: A rare form of liver cancer that typically affects young adults without liver disease.

Epidemiology of Hepatoma

Hepatoma is more common in certain regions due to differences in risk factors, such as hepatitis infections and environmental exposures. 

• The highest rates are observed in East Asia, sub-Saharan Africa, and Southeast Asia, where chronic hepatitis B and C infections are prevalent. 
• In contrast, North America and Western Europe have lower incidence rates, but cases have been rising due to alcohol-related liver disease, obesity, and non-alcoholic fatty liver disease (NAFLD).

Demographic Factors

Demographic factors may influence the risk and occurrence of hepatoma:

• Gender: Men are 2 to 4 times more likely to develop hepatoma than women, possibly due to higher exposure to risk factors such as alcohol use, smoking, and hepatitis infections.
• Age: Hepatoma typically develops after the age of 50, but in regions with high hepatitis B prevalence, cases can appear earlier due to childhood infections leading to chronic liver disease.

Causes of Hepatoma

While hepatoma can develop due to multiple factors, certain conditions increase a person’s risk. Some of these are preventable, while others, like genetics, are beyond a person's control. 

Common Causes

Many cases of hepatoma arise from pre-existing liver conditions that lead to long-term inflammation and scarring.

• Chronic hepatitis B and C infections 
• Cirrhosis and liver disease
• Non-alcoholic fatty liver disease (NAFLD) 

Rare Causes

Some less common causes of hepatoma include:

• Genetic mutations: Some inherited conditions (such as hereditary hemochromatosis) can increase the risk of liver cancer.
• Environmental toxins: Long-term exposure to aflatoxins can damage liver cells.

Risk Factors

Certain lifestyle and environmental factors increase the likelihood of developing hepatoma.

• Excessive alcohol consumption: Regular, heavy alcohol use damages liver cells, resulting in scarring and inflammation and an increased risk of liver cancer.
• Metabolic disorders: Diabetes and obesity have been linked to a higher incidence of liver cancer.

Symptoms of Hepatoma

Hepatoma symptoms can be subtle in the early stages and become more severe as the disease progresses. Recognizing the warning signs can lead to earlier diagnosis and better treatment outcomes.

Early-Stage Symptoms

In the beginning, hepatoma may not cause noticeable symptoms, but some early signs may include:

• Unexplained weight loss
• Fatigue and weakness
• Loss of appetite 

Advanced-Stage Symptoms

As hepatoma progresses, the liver's function becomes increasingly impaired, leading to:

• Abdominal pain and swelling: Fullness or discomfort, particularly in the upper right abdomen or near the right shoulder blade.
• Jaundice: Yellowing of the skin and eyes due to liver dysfunction.
• Itching
• Enlarged veins on the stomach 
• Swelling in the legs: Fluid buildup (edema) due to poor liver function.

Rare and Atypical Symptoms

In some cases, hepatoma can cause unusual symptoms due to its impact on metabolism and hormones.

• Paraneoplastic syndromes: Liver tumors can sometimes cause hormonal imbalances, leading to high calcium levels or low blood sugar.
• Neurological symptoms: Confusion or changes in behavior due to toxins accumulating in the bloodstream.

Differential Diagnosis 

Hepatoma shares symptoms with several other liver conditions. However, specialized imaging and biomarker testing, such as measuring alpha-fetoprotein (AFP) levels, help distinguish hepatoma from these conditions.

Benign Liver Lesions

• Hepatic Hemangioma 
• Focal Nodular Hyperplasia (FNH) 
• Hepatic Adenoma 

Other Primary Liver Cancers

• Cholangiocarcinoma (Bile Duct Cancer) 
• Hepatoblastoma – Occurs almost exclusively in young children.
• Fibrolamellar Carcinoma 

Metastatic Liver Disease

• Metastases to the Liver from Other Cancers – The liver is a common site for metastases from colorectal cancer, pancreatic cancer, lung cancer, and breast cancer. 

Infectious and Inflammatory Liver Diseases

• Liver Abscess 
• Granulomatous Liver Disease

Diagnosis of Hepatoma

Healthcare providers confirm the presence and severity of the disease using a combination of imaging, blood tests, and biopsy.

Diagnostic Tests

Tests used to diagnose and assess hepatoma:

• Imaging techniques: Ultrasound, CT scans, and MRI help visualize liver tumors. These tests provide information about the tumor’s size, characteristics, and invasion into other body parts.
• Blood tests and biomarkers: Elevated alpha-fetoprotein (AFP) levels may indicate liver cancer.
• Biopsy: A sample of liver tissue is examined under a microscope to confirm cancer and its characteristics.

Staging and Prognosis

Determining the stage of hepatoma helps doctors and cancer teams plan the best treatment approach. Commonly used cancer staging systems include: 

• Barcelona Clinic Liver Cancer (BCLC) Staging System: Classifies liver cancer based on tumor size, liver function, and patient health.
• TNM Staging System: Evaluates tumor spread to nearby tissues and distant organs.

Prognosis of Hepatoma (HCC)

The prognosis of hepatoma depends on several factors:

• Tumor Size and Number: Smaller tumors have a better prognosis, while multiple or large tumors indicate more advanced disease.
• Tumor Stage: Early-stage HCC (confined to the liver) has higher survival rates compared to advanced-stage disease with vascular invasion or distant metastases.
• Liver Function: Child-Pugh score assesses liver function.
• Presence of Vascular Invasion: If the tumor spreads into major blood vessels (e.g., portal vein thrombosis), the prognosis significantly declines due to the increased risk of metastasis.
• Treatment Approach: Curative treatments (surgical resection or liver transplantation) typically offer the best outcomes, while systemic therapies (targeted drugs, immunotherapy) improve survival in advanced cases.
• Response to Therapy: Patients who respond well to targeted therapy have better long-term outcomes.
• General Health: Patients with good overall health tolerate treatments better and have improved survival rates.

Early diagnosis and intervention significantly improve prognosis, emphasizing the importance of regular screening for high-risk individuals.

Treatment Options for Hepatoma

Treatment plans for hepatoma depend on the cancer stage and overall liver function. While conventional therapies like surgery and targeted medications are widely used, some patients explore complementary approaches, which should always be discussed with a healthcare provider.

Conventional Medical Treatments

Traditional medical therapies include:

• Surgery: Removing part of the liver if the tumor is localized.
• Liver transplantation: A complete liver replacement in eligible patients.
• Locoregional therapies: Transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) target liver cancers.  

Systemic Therapies

Systemic (body-wide) treatments may be necessary for patients with advanced hepatoma.

• Chemotherapy and targeted therapies: Studies support that drugs like sorafenib and lenvatinib have been shown to help slow tumor growth.
• Immunotherapy advancements: Checkpoint inhibitors (e.g., PD-1, PD-L1, CTLA-4 inhibitors) have been shown to help fight hepatoma.

Integrative and Functional Approaches

Some patients explore integrative treatments alongside medical care.

• Nutritional support and diet: A balanced diet may help support liver health.
• Complementary therapies: Acupuncture and herbal medicine may improve overall well-being but should be used under medical supervision.

Living with Hepatoma

A hepatoma diagnosis can be life-changing, but proper management and support can improve quality of life.

Managing Symptoms and Side Effects

• Pain management strategies: Medications and palliative care can help relieve discomfort.
• Coping with fatigue and emotional stress: Psychological support and lifestyle adjustments may improve well-being.

Support Systems and Resources

• Support groups and counseling: Connecting with others facing hepatoma can provide emotional relief.
• Financial and logistical support: On-line organizations can help with treatment costs and transportation.

Research and Future Directions

Advancements in liver cancer treatment continue to improve outcomes for patients. Researchers are exploring new therapies that may offer better survival rates, especially when hepatoma is detected early.

Current Research Trends

• Advances in genetic research: Scientists are exploring personalized treatments based on biomarkers and genetic factors.
• Innovations in treatment modalities: New targeted therapies and immunotherapy drugs show promise. Examples include: 
  
  • Targeted Therapies with Tyrosine Kinase Inhibitors (TKIs): These medications block specific enzymes that promote tumor growth and the formation of new blood vessels supplying the tumor.
  • Immunotherapy Advancements: Checkpoint Inhibitors & Combination Therapies

• Other emerging innovations include advanced radioembolization techniques (Yttrium-90 microspheres.
• Healthcare providers and patients can search for suitable clinical trials, providing access to cutting-edge treatments.

[signup]

Key Takeaways

• Hepatoma (Hepatocellular Carcinoma - HCC) is the most common type of liver cancer, often linked to chronic liver diseases such as hepatitis B, hepatitis C, and cirrhosis.
• Early symptoms can be subtle and may include unexplained weight loss, fatigue, and loss of appetite, while advanced stages can cause abdominal pain, jaundice, and severe liver dysfunction.
• Diagnosis relies on imaging tests (CT, MRI, ultrasound), blood tests (AFP levels), and liver biopsy, which help determine the stage and best course of treatment.
• Treatment options vary based on tumor stage and liver function, ranging from surgery and liver transplantation for early cases to chemotherapy, targeted therapies, and immunotherapy for advanced cases.
• Lifestyle modifications, including a liver-friendly diet, avoiding alcohol, and maintaining a healthy weight, may help slow disease progression and improve overall health.
• New research and clinical trials are advancing treatment options, with personalized medicine, genetic research, and immunotherapy showing promise for improved outcomes.
• Early detection is crucial for better survival rates, so individuals at high risk (such as those with chronic liver disease) should undergo regular screenings and medical check-ups.